Alzheimer’s Disease: Therapeutics
In our AD Therapeutics Deep Dive, we delve into the various factors contributing to the high failure rate of drug development for Alzheimer’s Disease and the reasons behind it. Learn about the complexities of the disease and the challenges in identifying effective therapies, from understanding the genetic and environmental factors to developing accurate diagnostic tools and biomarkers.
Discover the innovative approaches being taken by researchers and pharmaceutical companies to overcome these hurdles. Gain insights into the latest advancements in the field, such as targeting amyloid-beta, tau protein, and neuroinflammation, as well as exploring novel therapeutic targets and strategies, including gene therapy, stem cell therapy, and personalized medicine.
Hear from renowned experts in Alzheimer’s research, who share their perspectives on the current state of AD therapeutics development and the direction in which the field is headed. Understand the importance of collaboration between academia, industry, and regulatory bodies to accelerate the development of effective treatments for Alzheimer’s Disease.
Learn about the role of clinical trials in AD drug development and the efforts to improve trial recruitment, design, and efficiency. Find out how the global research community is working together to overcome the challenges in AD therapeutics development and move towards a brighter future for those affected by this devastating disease.
Watch our Alzheimer’s Disease Therapeutics Deep Dive to stay informed on the latest research, breakthroughs, and challenges in the quest for effective treatments for Alzheimer’s Disease.
- Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry
- Scientists Say They Have Developed A Memory-Restoring Prosthetic For The Human Brain
- FDA-approved treatments for Alzheimer’s
- Treatment Horizon
- A Vast Unmet Need: Challenges In Alzheimer’s Clinical Trials
- Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?
- Alzheimer's Drugs in Development Pipeline
- Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update
- Alzheimer's disease drug development pipeline: 2018
- Alzheimer's Drug Trials Keep Failing -- It May Be Because We Don't Understand the Disease
- Azeliragon: The third Alzheimer’s failure of 2018
- CLOSING IN ON A CURE: 2017 Alzheimer's Clinical Trials Report
- Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer’s Disease?